MeiraGTx Holdings PLC (FRA:328)
€ 6.1 -0.2 (-3.17%) Market Cap: 500.99 Mil Enterprise Value: 466.77 Mil PE Ratio: 0 PB Ratio: 5.50 GF Score: 47/100

MeiraGTx Holdings PLC at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2021 / 02:30PM GMT
Release Date Price: €10.9 (-2.68%)
Geulah Livshits
Chardan Capital Markets LLC - Analyst

It's now my pleasure to introduce our next fireside chat guest. From MeiraGTx, we have Dr. Zandy Forbes, President and Chief Executive Officer. Thank you, Zandy, for joining us today.

Zandy Forbes
MeiraGTx Holdings PLC - President & CEO

Thank you for having me. I'm happy to be here.

Geulah Livshits
Chardan Capital Markets LLC - Analyst

So Zandy, maybe we can start off by you providing us with a couple minutes of introductory comments on Meira and as well perhaps comment on any recent business developments and upcoming catalysts that we should keep in mind.

Zandy Forbes
MeiraGTx Holdings PLC - President & CEO

Thank you. So Meira is a gene therapy company currently focused in AAV. We have six clinical programs, with two entering pivotal studies. We have four programs in rare eye diseases. Our rare eye disease franchise is partnered with Janssen and our lead program there is in RPGR. We have a deep

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot